A world-class specialty pharmaceutical company
Our ambition is to become a leading specialty pharmaceutical company meeting the needs of patients around the world. With our portfolio of respiratory products we’re making good progress towards achieving our goal.
Press Releases
- Circassia Announces FDA Approval of Duaklir® for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
- Circassia Announces FDA Approval of Tudorza® Supplemental New Drug Application
- Circassia Announces Successful Completion of FDA Pre-submission Meeting for Novel Nitric Oxide Product AirNOvent
